Back to top
more

Xencor (XNCR)

(Delayed Data from NSDQ)

$19.23 USD

19.23
399,225

+0.21 (1.10%)

Updated Apr 25, 2024 03:59 PM ET

After-Market: $19.25 +0.02 (0.10%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of -186.11% and 68.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Xencor (XNCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 59.34% and 119.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 33.33% and 40.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?

by Zacks Equity Research

Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 75.90% and 8.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 69.3% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Xencor (XNCR) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Xencor (XNCR) points to a 74.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 28.57% and 78.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues

by Zacks Equity Research

Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Zacks.com featured highlights Xencor, Encore Wire and Silvergate Capital

by Zacks Equity Research

Xencor, Encore Wire and Silvergate Capital have been highlighted in this Screen of The Week article.

Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised

by Zacks Equity Research

JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.